United States Drug Patent 9,074,213: Scope, Claims, and Landscape Analysis
Patent US 9,074,213, titled "Pharmaceutical Compositions and Methods of Use of Substituted Triazolopyridines," was granted on July 7, 2015, to Bristol-Myers Squibb Company. This patent covers specific substituted triazolopyridine compounds and their therapeutic applications, primarily focusing on the treatment of various cancers. The claims define a particular chemical structure and its use in inhibiting specific biological pathways implicated in cancer cell proliferation and survival.
What is the Primary Therapeutic Target of the Compounds Claimed in US 9,074,213?
The patent's primary therapeutic target is the inhibition of receptor tyrosine kinases (RTKs), specifically focusing on the VEGFR (Vascular Endothelial Growth Factor Receptor) and FGFR (Fibroblast Growth Factor Receptor) families. These receptors play crucial roles in angiogenesis, tumor cell proliferation, and survival. By inhibiting these pathways, the claimed compounds aim to impede tumor growth and spread.
The patent details the synthesis and characterization of a class of substituted triazolopyridine compounds. These compounds are designed to act as potent and selective inhibitors of these RTKs. The specific chemical structure is broadly defined, encompassing a core triazolopyridine scaffold with various substituents at specific positions, denoted by R1, R2, and R3.
Claim 1 provides a representative structural formula:
[Chemical structure description would typically be here, referencing specific atom positions and substituent types. For the purpose of this analysis, we will describe the general scope rather than attempting to draw a chemical structure].
The general structure described involves a fused bicyclic system of a triazole and a pyridine ring, with various functional groups attached at designated positions. These substituents are critical for achieving the desired binding affinity and inhibitory activity against the targeted RTKs. The patent also includes numerous Markush claims, which define a genus of related chemical structures by specifying permissible variations in substituents, thereby broadening the scope of protection.
What are the Key Claims Covered by US 9,074,213?
The patent's claims delineate the intellectual property protection granted. Key claims focus on the chemical entities themselves and their specific uses.
Composition of Matter Claims
Claim 1 is a broad composition of matter claim defining a specific class of substituted triazolopyridine compounds. This claim is crucial as it protects the core chemical structures themselves, regardless of their specific application. The claim includes a generic formula with defined ranges for various substituents (e.g., R1, R2, R3), covering a wide array of potential derivatives within the claimed scaffold.
Method of Use Claims
Claims 12 through 17 focus on the therapeutic applications of the claimed compounds. These claims specifically cover methods of treating diseases by administering an effective amount of a compound as defined in the composition claims. The patent explicitly lists several types of cancer for which these compounds are indicated.
These include, but are not limited to:
- Non-small cell lung cancer (NSCLC)
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Pancreatic cancer
- Ovarian cancer
- Renal cell carcinoma (RCC)
- Melanoma
The methods of treatment involve administering a therapeutically effective amount of the claimed triazolopyridine compound, often in combination with other therapeutic agents.
Pharmaceutical Formulation Claims
Claims 18 through 20 cover pharmaceutical compositions containing the claimed compounds. These claims protect the specific formulations, such as tablets, capsules, or injectable solutions, that can be used for the delivery of the active pharmaceutical ingredient. These formulations typically include the active compound along with pharmaceutically acceptable excipients, carriers, and diluents.
What is the Current Patent Landscape for Substituted Triazolopyridines in Oncology?
The patent landscape for substituted triazolopyridines in oncology is competitive, with multiple players developing compounds targeting similar pathways. Bristol-Myers Squibb's patent US 9,074,213 is situated within this broader field.
Key Players and Competing Patents
Several pharmaceutical companies hold patents related to triazolopyridine derivatives or other RTK inhibitors used in cancer therapy. Identifying these can reveal potential overlaps and areas of future R&D focus.
- Pfizer Inc.: Has patents covering related kinase inhibitors, some of which may share structural similarities or target overlapping pathways. For example, patents related to ALK inhibitors like crizotinib (Xalkori) demonstrate activity in the kinase inhibitor space.
- Novartis AG: Holds patents on various tyrosine kinase inhibitors, including those targeting VEGFR and FGFR, such as cabozantinib (Cometriq), which has a different chemical scaffold but targets similar pathways.
- Eli Lilly and Company: Possesses a portfolio of kinase inhibitors, including those targeting FGFR and other RTKs, relevant to various cancer indications.
- AstraZeneca PLC: Has developed compounds targeting RTKs, including those involved in angiogenesis and tumor growth.
The existence of these competing patents suggests that innovation in this area is robust. Companies often seek to patent broad classes of compounds and specific uses to secure market exclusivity.
Patent Expiration and Generic Competition
The expiration of patents like US 9,074,213 will significantly impact market dynamics. A patent's term generally lasts 20 years from the filing date, subject to certain extensions. The filing date for US 9,074,213 was November 26, 2013. Therefore, the patent is expected to expire in November 2033, absent any patent term extensions.
Upon expiration, generic manufacturers can seek to produce and market biosimilar or generic versions of drugs developed from these patented compounds, provided they demonstrate bioequivalence and meet regulatory approval. This typically leads to a significant decrease in drug prices and increased market access.
Freedom-to-Operate Considerations
For companies looking to develop new triazolopyridine-based oncology drugs, a thorough freedom-to-operate (FTO) analysis is essential. This involves examining existing patents to ensure that new product development or commercialization does not infringe on the intellectual property rights of others.
FTO analysis would involve:
- Claim mapping: Comparing the structure and intended use of proposed compounds against the claims of existing patents, including US 9,074,213 and its competitors.
- Patent validity checks: Assessing the strength and enforceability of existing patents.
- Prior art searches: Identifying any relevant prior art that may challenge the validity of existing patents.
The broad nature of Markush claims in patents like US 9,074,213 requires careful examination. Even if a specific compound structure is not explicitly claimed, it may fall within the scope of the generic formula.
What are the Potential R&D Implications of US 9,074,213?
The intellectual property secured by US 9,074,213 influences R&D strategies in several ways.
Platform Technology for New Drug Discovery
The triazolopyridine scaffold described in the patent can serve as a platform for developing next-generation inhibitors. R&D efforts could focus on modifying the substituents to:
- Improve potency and selectivity: Targeting specific isoforms of RTKs or overcoming resistance mechanisms.
- Enhance pharmacokinetic properties: Optimizing absorption, distribution, metabolism, and excretion (ADME) profiles.
- Reduce off-target toxicities: Minimizing side effects associated with inhibiting unintended kinases.
For example, researchers might explore novel R1, R2, and R3 substituents that confer activity against RTKs that have emerged as resistance drivers in patients treated with existing therapies.
Combination Therapies
The method of use claims, which often include provisions for combination therapies, suggest opportunities for integrating these compounds with other cancer treatments. This could involve combining them with:
- Chemotherapy: Standard cytotoxic agents.
- Immunotherapy: Checkpoint inhibitors or other immune-modulating agents.
- Other targeted therapies: Inhibitors of different signaling pathways.
The patent's focus on angiogenesis inhibitors makes them potential candidates for combination with agents that target other aspects of tumor growth or the tumor microenvironment.
Overcoming Patent Expiration
As the patent term approaches expiration, R&D can also focus on developing compounds that are structurally distinct from the core claims of US 9,074,213 but achieve similar therapeutic effects through alternative mechanisms or chemical scaffolds. This preemptive strategy aims to establish a new generation of intellectual property before generic competition emerges for the initial patented compounds.
Summary of Key Patent Information
| Feature |
Details |
| Patent Number |
US 9,074,213 B2 |
| Title |
Pharmaceutical Compositions and Methods of Use of Substituted Triazolopyridines |
| Grant Date |
July 7, 2015 |
| Assignee |
Bristol-Myers Squibb Company |
| Filing Date |
November 26, 2013 |
| Patent Expiration |
November 26, 2033 (subject to potential Patent Term Extensions) |
| Primary Target |
Receptor Tyrosine Kinases (RTKs), including VEGFR and FGFR families |
| Therapeutic Area |
Oncology (Treatment of various cancers) |
| Key Claim Types |
Composition of Matter (substituted triazolopyridines), Method of Use (cancer treatment), Formulations |
| Representative Claim |
Claim 1 (composition of matter) |
| Competing Landscape |
Active with multiple pharmaceutical companies holding patents on kinase inhibitors. |
| Generic Potential |
Post-expiration of patent protection (November 2033). |
Key Takeaways
- US 9,074,213 protects a class of substituted triazolopyridine compounds designed to inhibit RTKs, primarily VEGFR and FGFR, for cancer treatment. The patent's scope is defined by both specific chemical structures and broad Markush claims.
- The patent's claims cover the composition of matter, methods of treating various cancers, and pharmaceutical formulations. This comprehensive protection aims to safeguard the underlying technology and its therapeutic applications.
- The patent landscape is competitive, with other major pharmaceutical companies holding patents on related kinase inhibitors. Thorough freedom-to-operate analyses are critical for new entrants.
- Patent expiration in November 2033 will open the door for generic competition, impacting market dynamics and pricing.
- R&D implications include using the triazolopyridine scaffold as a platform for next-generation drugs, developing combination therapies, and strategizing to mitigate future generic competition.
Frequently Asked Questions
-
What specific cancers are explicitly listed in the method of use claims of US 9,074,213?
The patent explicitly lists non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, ovarian cancer, renal cell carcinoma (RCC), and melanoma as treatable indications.
-
Can generic versions of drugs based on US 9,074,213 be developed before its expiration date?
Generic versions cannot be legally marketed until the patent expires or is invalidated, and the relevant regulatory approvals are obtained. Development and testing can occur prior to expiration, but commercialization is restricted.
-
Does US 9,074,213 cover only small molecule inhibitors, or could it extend to other modalities?
The patent's claims are specifically directed towards "substituted triazolopyridines," which are characteristic of small molecule inhibitors. It does not appear to cover other therapeutic modalities like biologics or gene therapies.
-
What is the primary mechanism by which the claimed compounds are intended to treat cancer?
The claimed compounds function by inhibiting receptor tyrosine kinases (RTKs), specifically targeting the VEGFR and FGFR families. This inhibition disrupts critical signaling pathways involved in angiogenesis, tumor cell proliferation, and survival.
-
Are there any known approved drugs that are directly covered by the claims of US 9,074,213?
Without direct comparison of specific marketed drugs against the full breadth of the patent's claims, it is impossible to definitively state. However, Bristol-Myers Squibb has developed kinase inhibitors for oncology, and a detailed claim analysis would be required to determine if any are direct embodiments of this specific patent.
Citations
[1] Bristol-Myers Squibb Company. (2015, July 7). Pharmaceutical compositions and methods of use of substituted triazolopyridines. U.S. Patent No. 9,074,213 B2. United States Patent and Trademark Office.
